Abeona Therapeutics Inc.
ABEO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -100% | 147.5% | -52.9% | – |
| Gross Profit | -$0 | $0 | $0 | $0 |
| % Margin | – | 54.1% | 68.2% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -1,444.9% | -2,431.6% | -2,560.5% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -1,548.2% | -2,807.4% | -2,831.2% |
| EPS Diluted | -1.55 | -2.53 | -5.53 | -21.5 |
| % Growth | 38.7% | 54.2% | 74.3% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |